AMLX

AMLX EBITDA Growth

20.14%TTM

Period ending:

AMLX TTM EBITDA YoY %%
AMLX TTM EBITDA YoY %617.17%-4436.54%
2022-09-302026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

AMLX ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 16 observations from Sep 30, 2022 to Jun 30, 2026.

Amylyx Pharmaceuticals Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
20.1411%
32.4777%
52.7713%
41.7628%
-16.3231%
-239.3636%
-643.8873%
-3,947.4719%
-131.1192%
56.4002%
128.098%
103.6323%
54.3755%
-22.1485%
-128.6069%
-175.9625%

Compare ebitda growth

All AMLX financial metrics · AMLX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.